Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE study
Genetic studies have shown lipoprotein(a) (Lp[a]) to be an important causal risk factor for coronary disease. Apolipoprotein(a) isoform size is the chief determinant of Lp(a) levels, but its impact on the benefits of therapies that lower Lp(a) remains unclear.
HPS2-THRIVE (Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events) is a randomized trial of niacin–laropiprant versus placebo on a background of simvastatin...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
(Version of record, pdf, 202.1KB)
- Publisher copy:
- Copyright holder:
- Parish et al
- Copyright date:
- © 2018 The Authors. Circulation: Genomic and Precision Medicine is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.
- CC Attribution (CC BY)